According to the recommendations for ALK-positive advanced NSCLC in the 2019 NCCN guidelines, the patient began oral treatment with crizotinib (250 mg twice daily) in November 2019 immediately after the identification of the TTC7A-ALK fusion gene. Here, ALK is linked to non-small cell lung carcinoma.